



Patent
Office

9/85 29

30 NOVEMBER 1999

INVESTOR IN PEOPLE

GB99/3972

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 13 JAN 2000

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signe *Andrew Gersey*

Dated 13 December 1999

35 DEC 1998

07DEC98 0404380-1 000934

0700 0.00 - 9826747.9

9826747.9

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent
(See notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

PHM98-141/GB/P

2. Patent application number

(The Patent Office will fill in this part)


3. Full name, address and postcode of the or of each applicant (underline all surnames)

ZENECA Limited
15 Stanhope Gate
London W1Y 6LN
GB

Patents ADP number (if you know it)

6254007002

If the applicant is a corporate body, give the country/state of its Incorporation



4. Title of the invention

CHEMICAL COMPOUNDS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GILES, Allen Frank
Intellectual Property Department
ZENECA Pharmaceuticals
Mereside, Alderley Park
Macclesfield
Cheshire
SK10 4TG, GB

Patents ADP number (if you know it)

6988463001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d)).

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing *in* this form. Do not count copies of the same document.

Continuation sheets of this form

Description 13

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(*please specify*)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

04 December 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

MRS LYND A M SLACK - 01625 516173

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

CHEMICAL COMPOUNDS

This invention relates to polymorphisms in the Factor X gene. The invention also relates to methods and materials for analysing allelic variation in the Factor X gene, and to the use of
5 Factor X polymorphism in the diagnosis and treatment of Factor X and/or Factor Xa-mediated diseases, such as thrombotic diseases.

Factor Xa is one of a cascade of proteases involved in the complex process of blood coagulation. The protease known as thrombin is the final protease in the cascade and Factor Xa is the preceding protease which cleaves prothrombin to generate thrombin. Factor Xa is
10 produced by cleavage of the zymogen precursor Factor X, by activated factor VII. For a review of the process of blood coagulation see Rock and Wells (1997) Crit Rev Clin Lab Sci 34, 475-501 and for a review of the Biochemistry of Factor X see Hertzberg (1994) Blood Reviews 8, 56-62.

Certain compounds are known to possess Factor Xa inhibitory properties and the
15 field has been reviewed by R.B. Wallis, Current Opinion in Therapeutic Patents, 1993, 1173-1179 and Yamazaki (1995) Drugs of the Future 20, 911-918. Thus it is known that two proteins, one known as antistatin and the other known as tick anticoagulant protein (TAP), are specific Factor Xa inhibitors which possess antithrombotic properties in various animal models of thrombotic disease.

20 It is also known that certain non-peptidic compounds possess Factor Xa inhibitory properties. Of the low molecular weight inhibitors mentioned in the review by R.B. Wallis, all possessed a strongly basic group such as an amidinophenyl or amidinonaphthyl group.

The sequence of Factor X was published by Leytus et al (1986) Biochemistry 25, 5098-5102. The sequence was submitted to the EMBL database as separate exons: Exon 1
25 (EMBL Accession Number - L00390), Exon 2 (EMBL Accession Number - L00391), Exon 3 (EMBL Accession Number - L00392), Exon 4 (EMBL Accession Number - L00393), Exon 5 (EMBL Accession Number - L00394), Exon 6 (EMBL Accession Number - L00395), Exon 7 (EMBL Accession Number - L00396), and Exon 8 (EMBL Accession Number - L29433). All positions herein relate to the position in the appropriate EMBL Accession number unless
30 stated otherwise or apparent from the context.

Mutations in the Factor X gene which lead to Factor X deficiency and a clinical phenotype are well documented (For a review of Factor X mutations and Factor X deficiency see Cooper et al (1997) *Thrombosis and Haemostasis* 78, 161-172).

Other variation in DNA sequence (polymorphisms) may not lead to Factor X deficiency but may increase the probability of pathological conditions or affect drug response or may be genetically linked to other polymorphisms which do so.

One approach is to use knowledge of polymorphisms to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), *Clinical Chemistry*, 43, 254; Marshall (1997), *Nature Biotechnology*, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), *Nature Biotechnology*, 16, 33.

Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

The present invention is based on the discovery of two single nucleotide polymorphisms (SNPs) in the coding sequence of the human Factor X gene.

According to one aspect of the present invention there is provided a method for the diagnosis of a single nucleotide polymorphism in a Factor X gene in a human, which method comprises determining the sequence of the nucleic acid of the human at position 41 in exon 5 of the Factor X gene as defined by the position in EMBL
ACCESSION NO. L00394, and/or
at position 57 in exon 7 of the Factor X gene as defined by the position in EMBL
ACCESSION NO. L00396 and determining the status of the human by reference to polymorphism in the Factor X gene.

According to another aspect of the present invention there is provided a method for the diagnosis of a single nucleotide polymorphism in a Factor X gene in a human, which method comprises determining the sequence of the nucleic acid of the human

at position 41 in exon 5 of the Factor X gene as defined by the position in EMBL
ACCESSION NO. L00394, and/or

at position 57 in exon 7 of the Factor X gene as defined by the position in EMBL
ACCESSION NO. L00396 and determining the status of the human by reference to

5 polymorphism in the Factor X gene.

The term human includes both a human having or suspected of having a Factor X-
mediated disease and an asymptomatic human who may be tested for predisposition or
susceptibility to such disease. At each position the human may be homozygous for an allele
or the human may be a heterozygote.

10 In one embodiment of the invention preferably the method for diagnosis described herein
is one in which the single nucleotide polymorphism at exon 5 position 41 is presence of C
and/or T.

In another embodiment of the invention preferably the method for diagnosis described
herein is one in which the single nucleotide polymorphism at exon 7 position 57 is presence of
15 C and/or T.

The method for diagnosis is preferably one in which the sequence is determined by a
method selected from amplification refractory mutation system and restriction fragment
length polymorphism.

In another aspect of the invention we provide a method for the diagnosis of Factor X-
20 and/or Factor Xa-mediated disease, which method comprises:

- i) obtaining sample nucleic acid from an individual,
- ii) detecting the presence or absence of a variant nucleotide at position 41 in exon 5 of the
Factor X gene as defined by the position in EMBL ACCESSION NO. L00394, and/or
at position 57 in exon 7 of the Factor X gene as defined by the position in EMBL
25 ACCESSION NO. L00396,
- iii) determining the status of the individual by reference to polymorphism in the Factor X
gene.

Allelic variation at exon 5 position 41 consists of a single base substitution from C (the
published base), preferably to T. Allelic variation at exon 7 position 57 consists of a single
30 base substitution from C (the published base), preferably to T.

The status of the individual may be determined by reference to allelic variation at any one or both positions optionally in combination with any other polymorphism that is or becomes known.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

ALEX TM	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS TM	Amplification refractory mutation system
b-DNA	Branched DNA
CMC	Chemical mismatch cleavage
bp	base pair
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
FRET	Fluorescence resonance energy transfer

LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis

Table 1 - Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation

- 5 Scanning: PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

* Note: not useful for detection of promoter polymorphisms.

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide
10 arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)

Extension Based: ARMST™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca
15 Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

Incorporation Based: Mini-sequencing, APEX

Restriction Enzyme Based: RFLP, Restriction site generating PCR

Ligation Based: OLA

Other: Invader assay

5 Table 2 - Signal Generation or Detection Systems

Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

10

Table 3 - Further Amplification Methods

SSR, NASBA, LCR, SDA, b-DNA

Preferred mutation detection techniques include ARMSTM, ALEXTM, COPS, Taqman,
15 Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques.

Particularly preferred methods include ARMSTM and RFLP based methods. ARMSTM is an especially preferred method.

In a further aspect, the diagnostic methods of the invention are used to assess the efficacy of therapeutic compounds in the treatment of Factor X and/or Factor Xa-mediated diseases,
20 such as thrombotic diseases.

Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

Individuals who carry particular allelic variants of the Factor X gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different
25 physiological conditions and will display altered abilities to react to different diseases. In addition, differences in protein regulation arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The diagnostic methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose.

30 In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by Factor X and/or

Factor Xa. This may be particularly relevant in the development of thrombotic disease and other diseases which are modulated by Factor X and/or Factor Xa. The present invention may be used to recognise individuals who are particularly at risk from developing these conditions.

In a further aspect, the diagnostic methods of the invention are used in the development of
5 new drug therapies which selectively target one or more allelic variants of the Factor X gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.

10 In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes. In the accompanying Example 2 we provide details of convenient engineered restriction enzyme sites that are lost or gained as a result of a polymorphism of the invention.

15 According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymorphisms:
the nucleic acid of EMBL ACCESSION No. L00394 with T at position 41 as defined by the position in EMBL ACCESSION No. L00394;
the nucleic acid of EMBL ACCESSION No. L00396 with T at position 57 as defined by the
20 position in EMBL ACCESSION No. L00396;
or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

25 The invention further provides nucleotide primers which can detect the polymorphisms of the invention.

According to another aspect of the present invention there is provided an allele specific primer capable of detecting a Factor X gene polymorphism
at position 41 in exon 5 of the Factor X gene as defined by the positions in EMBL

30 ACCESSION NO. L00394, and/or

at position 57 in exon 7 in the Factor X gene as defined by the positions in EMBL
ACCESSION NO. L00396.

An allele specific primer is used, generally together with a constant primer, in an
amplification reaction such as a PCR reaction, which provides the discrimination between
5 alleles through selective amplification of one allele at a particular sequence position e.g. as
used for ARMS™ assays. The allele specific primer is preferably 17- 50 nucleotides, more
preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but
derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3'
10 terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4,
2, or 1 of the remaining nucleotides may be varied without significantly affecting the
properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of
such methods may be found in standard textbooks, for example "Protocols for
15 Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology
Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If
required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific
oligonucleotide probe capable of detecting a Factor X gene polymorphism
20 at position 41 in exon 5 of the Factor X gene as defined by the positions in EMBL
ACCESSION NO. L00394, and/or
at position 57 in exon 7 in the Factor X gene as defined by the positions in EMBL
ACCESSION NO. L00396.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably
25 about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill.
Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more
conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In
general such probes will comprise base sequences entirely complementary to the
30 corresponding wild type or variant locus in the gene. However, if required one or more
mismatches may be introduced, provided that the discriminatory power of the oligonucleotide

probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific
5 primer of the invention.

The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

In another aspect of the invention, the single nucleotide polymorphisms of this invention
10 may be used as genetic markers in linkage studies. This particularly applies to the polymorphism at exon 7 position 57 because of its informative frequency (see below). The Factor X gene has been mapped to chromosome 13q34 (Bowcock et al, Genomics 16, 486-496, 1993).

According to another aspect of the present invention there is provided a method of treating
15 a human in need of treatment with a Factor Xa ligand antagonist drug and/or a Factor X-modulating drug in which the method comprises:

- i) diagnosis of a single nucleotide polymorphism in Factor X gene in the human, which diagnosis comprises determining the sequence of the nucleic acid at position 41 in exon 5 of the Factor X gene as defined by the positions in EMBL
20 ACCESSION NO. L00394, and/or
at position 57 in exon 7 in the Factor X gene as defined by the positions in EMBL ACCESSION NO. L00396.
and determining the status of the human by reference to polymorphism in the Factor X gene; and
- 25 ii) administering an effective amount of a Factor Xa ligand antagonist drug and/or a Factor X-modulating drug.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which antagonist drug or drugs to administer and/or in deciding on the effective amount of the drug or drugs.

30 Inhibitors of Factor Xa have been disclosed in the following publications: European patent application EP 540051 A, Daiichi; WO9821188, Zeneca Ltd and WO9610022, Zeneca Ltd.

According to another aspect of the present invention there is provided use of a Factor Xa ligand antagonist drug and/or a Factor X-modulating drug in preparation of a medicament for treating a Factor Xa and/or Factor X-mediated disease in a human diagnosed as having a single nucleotide polymorphism

- 5 at position 41 in exon 5 of the Factor X gene as defined by the positions in EMBL
ACCESSION NO. L00394, and/or
at position 57 in exon 7 in the Factor X gene as defined by the positions in EMBL
ACCESSION NO. L00396.

- According to another aspect of the present invention there is provided a pharmaceutical
10 pack comprising a Factor X-ligand antagonist drug and/or a Factor X-modulating drug and
instructions for administration of the drug to humans diagnostically tested for a single
nucleotide polymorphism
at position 41 in exon 5 of the Factor X gene as defined by the positions in EMBL
ACCESSION NO. L00394, and/or
15 at position 57 in exon 7 in the Factor X gene as defined by the positions in EMBL
ACCESSION NO. L00396.

The invention will now be illustrated but not limited by reference to the following
Examples. All temperatures are in degrees Celsius.

- In the Examples below, unless otherwise stated, the following methodology and materials
20 have been applied.

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable
DNA polymerase.

- General molecular biology procedures can be followed from any of the methods described
in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and
25 Maniatis (Cold Spring Harbor Laboratory, 1989).

Electropherograms were obtained in a standard manner: data was collected by ABI377
data collection software and the wave form generated by ABI Prism sequencing analysis
(2.1.2).

Example 1**Identification of Polymorphisms****1. Methods**DNA Preparation

- 5 DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2nd Edition, Cold Spring Harbor Press, 1989) with the following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then
- 10 phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water.

Template Preparation

- Exons 5 and 7 were amplified from genomic DNA by PCR. Templates were prepared
- 15 using the oligonucleotide primers described below.

Exon 5 was amplified in a two step PCR reaction with an annealing temperature of 68° and denaturation temperature of 94°. Exon 7 was amplified in a three step PCR reaction with an annealing temperature of 64°, extension temperature of 72° and denaturation temperature of 94°. Each step was 1 minute. Both reactions were carried out in 1.0mM MgCl₂ buffer.

- 20 For analysis generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR.

Fragment	Forward Oligo 5'-3'	Reverse Oligo
Exon 5	ccagcctccatttctccagctg	ctggcaggtaacagtgacacca
Exon 7	caggcaacacctgtctacctg	gcaccgtcactgtctacttttca

Forward oligos were modified by the addition of M13 forward sequence to the 5' end for 25th use in dye-primer sequencing.

Dye Primer Sequencing

Dye-primer sequencing using M13 forward primer was as described in the ABI protocol P/N 402114 for the ABI Prism™ dye primer cycle sequencing core kit with "AmpliTaq FS"™ DNA polymerase, modified in that the annealing temperature was 45° and DMSO was added to the cycle sequencing mix to a final concentration of 5 %.

- 5 The extension reactions for each base were pooled, ethanol/sodium acetate precipitated, washed and resuspended in formamide loading buffer.

4.25 % Acrylamide gels were run on an automated sequencer (ABI 377, Applied Biosystems).

10 2. Results

Novel Polymorphisms

EMBL Sequence	Position	Published	Variant	RFLP	Frequency
L00394	41	C	T	eng Nco I	1/54
L00396	57	C	T	eng Spe I	39/48

Frequency is the allele frequency of the variant allele in control subjects.

- 15 "eng" = engineered RFLP

Example 2

Engineered restriction site primers for detection of polymorphisms

- Standard methodology can be used to detect the polymorphism at position 41 (as defined by the position in EMBL ACCESSION NO L00394) and the polymorphism at position 57 (as defined by the position in EMBL ACCESSION NO. L00396) based on the materials set out below using a cDNA template.

EMBL Sequence	Position	Diagnostic Fragment	Forward Oligo	Reverse Oligo
L00394	41	17-156	17-40 Nco I	126-156
L00396	57	1-81	1-21	58-81 Spe I

Primer Sequence 5'-3'

17-40 Nco I ACGGAAGCTCTGCAGCCTGGACCA

58-81 Spe I TAGGGATGTAGAACTCGCTCAGACT

- 5 T at position 41 generates an engineered Nco I site in the diagnostic fragment 17-156 described above. T at 57 generates an engineered Spe I site in the diagnostic fragment 1-81 as described above.